In recent years, nanotechnologies have enabled the design and development of systems offering novel approaches to traditional disease treatments. Among the various applications, lipid-based drug delivery systems have emerged as innovative nanoplatforms aimed at targeted delivery, improved drug biodistribution, and greater therapeutic efficacy, with a consequent reduction in side effects. Many drugs exhibit poor biodistribution and a preferential accumulation in the liver, the organ responsible for eliminating harmful substances from the body. This accumulation prevents the effective treatment of localized diseases, like cancer, which require the use of higher drug doses to reach the minimum therapeutic drug concentration in the targeted organ.